The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.